NCT05609214 Complementary Investigation of Perfusion and Anatomy Measures of the Heart With MRI and Combined PET/MRI
| NCT ID | NCT05609214 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-11-21 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-11-21 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate the complimentary information of anatomy, perfusion and viability of PET and MR. The main question\[s\] it aims to answer are: * to compare perfusion and anatomy measurements and perfusion related signals from PET and MR imaging and estimate its prognostic values. * to evaluate potential optimization of routine scanning procedure with regards to completeness and potential added value of quantitative measurements.
Eligibility Criteria
Inclusion Criteria: * Male and Female participants over the age of 18 years * Written informed consent by the participant after information about the research project * Symptoms consistent with possible coronary artery disease * Clinical referral for a vasodilator stress CMR and/or PET examination Exclusion Criteria: * Patients with high degree heart block * Contraindications to gadolinium-enhanced CMR examination * Severe claustrophobia * Specific implantable devices which are contraindicated for CMR * Current pregnancy * Advanced renal disease (GFR\<30) * Uncontrolled obstructive pulmonary disease or asthma * Atrial fibrillation at the time of study enrolment
Contact & Investigator
Aju P Pazhenkottil
PRINCIPAL INVESTIGATOR
University of Zurich
Frequently Asked Questions
Who can join the NCT05609214 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05609214 currently recruiting?
Yes, NCT05609214 is actively recruiting participants. Contact the research team at aju.pazhenkottil@usz.ch for enrollment information.
Where is the NCT05609214 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT05609214 clinical trial?
NCT05609214 is sponsored by University of Zurich. The principal investigator is Aju P Pazhenkottil at University of Zurich. The trial plans to enroll 200 participants.